Source Post
6/30 - INMB failure
Jun 30, 2025
The creator discusses the failure of an immune drug, noting that the primary endpoint was not met and the placebo even slightly outperformed the drug. He dismisses subgroup analyses as unreliable and suggests the company will likely not continue investing in this drug.
Linked Mentions
Tickers discussed in this post
Linked Signals
Tracked calls opened from this post
No linked signals were opened directly from this post.